Fact.MR – A Market Research and Competitive Intelligence Provider: Fact.MR projects the global respiratory virus vaccines market to expand at a healthy pace, exhibiting growth at an impressive CAGR of 7% between 2021 and 2031.
Respiratory Virus Vaccines Development to Attract 3X Higher Investment from Pharma Companies
The Fact.MR survey on respiratory virus vaccines market offers detailed analysis on the key growth drivers and trends affecting demand. The survey also provides insights into the competitive landscape, identifying the key market players and analyzing the impact of their growth strategies
Fact.MR – A Market Research and Competitive Intelligence Provider: Fact.MR projects the global respiratory virus vaccines market to expand at a healthy pace, exhibiting growth at an impressive CAGR of 7% between 2021 and 2031. Focus on vaccine discovery to contain the rising cases of viral infections across the globe will spur the growth.
The outbreak of COVID-19 for instance has spurred the demand for respiratory vaccines. Market players have therefore amplified their research and development efforts to find the effective cure for the diseases.
Favorable government policies are encouraging private and public organizations across the globe to increase their funding towards the development of vaccines. This will create impressive growth prospects for the key players. Alongside this, high prevalence of seasonal influenza, especially across the U.S. will provide impetus to the demand.
In 2020, around 38 million cases of influenza were reported in the U.S., estimates Centers for Disease Control and Prevention. Considering this burden, the demand for respiratory virus vaccines will continue to remain high over the coming years.
Governments around the world are actively investing in research & development to discover effective vaccine that will curb the impact of COVID-19. This trend will continue even after the pandemic passes, to protect the world against such unforeseen outbreaks.
“The focus on research initiatives and clinical trials will continue soaring through the forecast period. The market players are likely to focus on approval by leading international organizations to make deeper inroads in developed and developing economies, alike," said a Fact.MR analyst.
For More Information On How To Improve Your Respiratory Virus Vaccines Market Footprint, Request A Sample Here
https://www.factmr.com/connectus/sample?flag=S&rep_id=5199
Key Takeaways from Respiratory Virus Vaccines Market Research Report:
- Based on type, inactive/killed vaccines are expected to hold maximum share in the global market
- Intramuscular segment is likely to remain as the most preferred route of administration during the forecast period
- In terms of indication, influenza segment currently holds the prominence owing to the rising cases of influenza among children across the globe
- Pediatric segment will hold maximum share in terms of age group owing to the rising cases of respiratory diseases among children
- Rising penetration of physician across the globe will enable growth of the segment, however demand from hospitals too is expected to rise over the coming years
- The U.S. is expected to witness high growth during the forecast period owing to the growing focus on healthcare solutions
- The U.K. will emerge as the second leading market for respiratory virus vaccines by the end of 2031.
Growth drivers:
- High prevalence of infectious disease and growing focus on immunization programs will propel the market demand
- Favorable government policies for development of advanced vaccines will accelerate the growth
- Focus on therapeutic respiratory virus vaccines will improve the market demand by 2031.
Key restraints:
- High cost of the respiratory virus vaccine development is likely to restrict the market demand
- Inadequate access to vaccines, especially in developing economies, is expected to hamper the growth
Ask Your Respiratory Virus Vaccines Market Related Questions & Get Customized Reports
https://www.factmr.com/connectus/sample?flag=RC&rep_id=5199
Competitive Landscape
Burgeoning demand for vaccines around the world has led to intense competition in the market. Key manufacturers are adopting inorganic strategies such as product development, mergers, and collaborations to strengthen their global footprints.
Research and development activities among the key players for the development of effective vaccines is expected to surge over the coming years.
In April 2021, Sanofi announced positive results for its, Nirsevimab, vaccines which demonstrated protection against respiratory syncytial virus disease found within healthy infants in Phase 3 trial.
In October 2020, Moderna Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines to create a new generation of transformative medicines for patents announced that it has regained all rights to the respiratory syncytial virus vaccine (mRNA-1172) from Merck.
In 2019, Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has granted approval of Breakthrough Therapy Designation for the Company's investigational prophylactic vaccine for the prevention of respiratory syncytial virus (RSV)-mediated lower respiratory tract disease in adults aged 60 years or older.
Key players operating in the respiratory virus vaccines market are
- Bharat Biotech
- CSL Limited
- AstraZeneca
- Sanofi
- GlaxoSmithKline PLC
- Merck & Co. Inc.
- Serum Institute of India Pvt. Ltd.
- Sinovac Biotech Ltd.
- Others
More Insights on the Respiratory Virus Vaccines Market:
Fact.MR provides an unbiased analysis of the respiratory virus vaccines market, presenting historical demand data (2015-2019) and forecast statistics for the period from 2020-2030. The study divulges compelling insights on the global respiratory virus vaccines market with a detailed segmentation on the basis of:
Type:
- Inactivated/Killed Vaccines
- Live-attenuated Vaccines
- Recombinant Vaccines
Route of Administration:
- Intramuscular
- Intranasal
- Subcutaneous
Indication:
- Influenza
- Measles, Mumps & Rubella
- Coronavirus Disease (COVID-19)
- Others
Age Group:
- Pediatric
- Adults
End User:
- Physician Offices
- Hospitals
- Clinics
- Pharmacies/Stores
Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Key Questions Covered in the Respiratory Virus Vaccines Market Report
- The report offers detailed insights into respiratory virus vaccines demand outlook for 2021-2031
- The market study also highlights projected sales growth for respiratory virus vaccines market between 2021 and 2031
- Respiratory virus vaccines market survey identifies key growth drivers, restraints, and other forces impacting prevailing trends and evaluation of current market size and forecast and technological advancements within the industry
- Respiratory virus vaccines market share analysis of the key companies within the industry and coverage of strategies such as mergers & acquisitions, joint ventures, collaborations or partnerships, and others
Explore Fact.MR’s Coverage on the Healthcare Domain
Respiratory Syncytial Virus (RSV) Diagnostics Market - Asia Pacific is projected to have greater levels of respiratory syncytial virus diagnoses across the evaluation period. Increasing burdens with infectious diseases, including RSVs, are driving market development in the region and are focusing on emerging Asia Pacific countries. The landscape for the diagnosis of respiratory syncytial viruses is significantly fragmented in nature. Manufacturers rely on technical advancements to accelerate respiratory syncytial virus detection.
Influenza Diagnostics Market - An increase in awareness of the need of early disease identification among the global population is a major contributor to the growth of the global influenza diagnostic market. In order to avoid and eradicate the disease mortality, organizations take measures to encourage the practice of early diagnosis. RDIT was the greatest market share in 2020 as it is user-friendly and freely available, making efficient diagnosis easier.
Recombinant Protein Market - An increase in awareness of the need of early disease identification among the global population is a major contributor to the growth of the global influenza diagnostic market. In order to avoid and eradicate the disease mortality, organizations take measures to encourage the practice of early diagnosis. RDIT was the greatest market share in 2020 as it is user-friendly and freely available, making efficient diagnosis easier.
About Fact.MR
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.
Contact:
Mahendra Singh
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
Source: Fact.MR